Increased Risk of Meningioma Brain Tumors Linked to Depo-Provera® Birth Control Injections
- Call 858-256-7616 or email info@foxlawapc.com for more information or to discuss your legal rights.
- Depo-Provera® Linked to Increased Risk of Meningioma Brain Tumors: Recent studies have found that prolonged use of Depo-Provera® birth control injections significantly increases the risk of developing meningioma brain tumors.
- 5.6-Fold Increase in Risk: A study published in the British Medical Journal revealed that women using Depo-Provera® birth control injections for more than one year were almost six times more likely to develop meningioma brain tumors than non-users.
- Meningioma Brain Tumors May Require Surgical Intervention: These tumors can grow and exert pressure on the brain, often necessitating invasive brain surgery with serious health risks and many potential complications.
- Common Symptoms of Meningioma Brain Tumors: Common symptoms of meningioma brain tumors include persistent headaches, vision problems, seizures, hearing loss, and weakness in limbs.
- Manufacturer’s Potential Negligence: There are concerns that Pfizer® failed to adequately test Depo-Provera® birth control injections and did not provide proper warnings about the risks of developing meningioma brain tumors.
- Legal Rights to Compensation: If you developed a meningioma brain tumor after using Depo-Provera®, you may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more.
- Time Is of the Essence: Statutes of limitations apply; acting promptly is crucial to preserve your legal rights.
- Contact Us for a Free Consultation: Confidentially contact Fox Law to discuss your legal rights – www.foxlawapc.com; call 858-256-7616 or email info@foxlawapc.com.
What Is Depo-Provera®?
- Depo-Provera® is long-acting contraceptive used to prevent pregnancy. It is typically given as an intramuscular injection every 12 weeks.
- It is more than 99% effective when administered on schedule.
- Chosen by millions of women worldwide for its convenience and reliability.
- While Depo-Provera® has been a trusted contraceptive for many, recent studies have raised concerns about its safety and its potential link to meningioma brain tumors.
Key Takeaways from the Depo-Provera® – Brain Tumor Study
- Institutions Involved: French National Agency for Medicines and Health Products Safety (ANSM) and the French National Health Insurance.
- Publication: Findings were published in the British Medical Journal (BMJ), one of the world’s oldest and most respected peer-reviewed medical journals.
- Rigorous Peer Review: The BMJ’s stringent review process ensures the research is of high quality.
- Large Sample Size: Analyzing over 100,000 women’s medical records enhances reliability.
- Methodological Rigor: Adjustments for confounding factors strengthen the validity of conclusions.
- Alignment with Existing Research: Consistency with previous studies reinforces credibility.
- Read a study here.
- Read a news story here.
What Are Meningioma Brain Tumors?
- Approximately one-third of all primary brain tumors are meningiomas.
- They are typically non-cancerous but can be malignant in rare cases.
- They are often slow-growing, but size and location can affect neurological functions.
- Usually identified through MRI or CT scans after symptom presentation.
Your Legal Rights After a Meningioma Brain Tumor Diagnosis
Pharmaceutical companies are obligated to ensure product safety and inform consumers of potential risks with their drugs. Understanding the role of Pfizer Inc., the manufacturer of Depo-Provera®, is crucial. The following are Pfizer’s potential failures:
- Inadequate Research: Potential lack of comprehensive studies on long-term neurological effects.
- Overlooking Red Flags: Possible disregard of early adverse effect reports.
- Omission of Critical Information: Possible failure to include warnings about the increased risk of meningioma.
- Misleading Marketing: Potential for emphasizing benefits while downplaying serious risks.
- Failure to Report Adverse Events: Potential lack of timely reporting of meningioma cases linked to Depo-Provera®.
- Inadequate Response to New Evidence: Possible delay in updating warnings or conducting further research.